<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04510376</url>
  </required_header>
  <id_info>
    <org_study_id>OMZPRI1F</org_study_id>
    <nct_id>NCT04510376</nct_id>
  </id_info>
  <brief_title>Allergy Potential of Omeza Collagen Matrix in Human Subjects Using the Skin Prick Method</brief_title>
  <official_title>A Safety Study to Assess the Allergy Potential of Omeza Collagen Matrix in Human Subjects Using the Skin Prick Method</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Omeza, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Omeza, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single-center, monadic, one day study utilizing the skin prick method to assess the allergy&#xD;
      potential of Omeza Collagen Matrix in Human Subjects&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 14, 2019</start_date>
  <completion_date type="Actual">November 14, 2019</completion_date>
  <primary_completion_date type="Actual">November 14, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Allergic Reaction</measure>
    <time_frame>20 minutes</time_frame>
    <description>Response of at least 3-mm diameter (with equivalent erythema) more than negative control is required as proof of presence of cutaneous allergen specific IgE</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Allergic Reaction</measure>
    <time_frame>60 minutes</time_frame>
    <description>Latent reaction to skin prick (safety assessment)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Allergic Reaction</condition>
  <arm_group>
    <arm_group_label>Test article</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Histamine Positive Skin Test Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Aqueous Negative Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Test Article</intervention_name>
    <description>Omeza Collagen Matrix</description>
    <arm_group_label>Test article</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Positive Control</intervention_name>
    <description>1.0 mg/mL Histamine Base</description>
    <arm_group_label>Histamine Positive Skin Test Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Negative Control</intervention_name>
    <description>Aqueous Negative Control</description>
    <arm_group_label>Aqueous Negative Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy volunteers aged 18 years of age and older as demonstrated by selfreported&#xD;
             medical history, concurrent medication, and a brief dermal skin assessment of the test&#xD;
             sites;&#xD;
&#xD;
          2. Fully informed of the risks of entering the study and willing to provide written&#xD;
             informed consent and HIPAA authorization to disclose protected health information;&#xD;
&#xD;
          3. Subject has normal healthy skin on the either volar forearm.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects must be excluded if any of the following conditions exist:&#xD;
&#xD;
          1. Self-reported pregnant or nursing at the screening visit;&#xD;
&#xD;
          2. Clinically significant skin disease which may contraindicate participation, including&#xD;
             psoriasis, eczema, atopic dermatitis, and active cancer;&#xD;
&#xD;
          3. History of drug abuse or current drug user;&#xD;
&#xD;
          4. Treatment with antihistamine or steroid (any route) administered within the last 7&#xD;
             days;&#xD;
&#xD;
          5. History of anaphylaxis to matrix ingredients (e.g. fish, palm oil, hemp oil, beeswax);&#xD;
&#xD;
          6. Persistent severe/ unstable asthma;&#xD;
&#xD;
          7. Subjects on beta blockers and/or ACE inhibitors;&#xD;
&#xD;
          8. Medical condition which in the opinion of the Investigator would compromise the safety&#xD;
             of the subject or confound study results (Subjects with the following conditions:&#xD;
             chronic renal failure, CVA, cancer, spinal cord injury, diabetic neuropathy, recent&#xD;
             anaphylaxis, limbs affected by lymphoedema, paralysis, or neurogenic abnormalities;&#xD;
&#xD;
          9. Diabetic (type 1 or 2);&#xD;
&#xD;
         10. Subjects taking the following: Antidepressants such as doxepin, other tricyclics,&#xD;
             Phenothiazines, and tetracyclics within the last two weeks;&#xD;
&#xD;
         11. Subjects taking OTC cold and flu remedies, &quot;sinus&quot; analgesics, antitussives,&#xD;
             antiemetics, sedatives, relaxants, migraine prophylactics (cyproheptadine, pizotifen);&#xD;
&#xD;
         12. Prolonged use of topical corticosteroids;&#xD;
&#xD;
         13. Use of topical moisturizers on the volar forearms;&#xD;
&#xD;
         14. Dermographism &quot;writing on the skin&quot; - common localized hive reaction, characterized by&#xD;
             the abrupt onset of welts and hives where the skin is exposed to pressure, scratching,&#xD;
             itching, or stroking;&#xD;
&#xD;
         15. Investigator deems the subject an unsuitable candidate for this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lynne Ellis, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>PCR Corp</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lori Decaro</last_name>
    <role>Study Director</role>
    <affiliation>PCR Corp</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PCR Corp</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.aaaai.org/Aaaai/media/MediaLibrary/PDF%20Documents/Practice%20and%20Parameters/allergydiagnostictesting.pdf</url>
    <description>Allergy Diagnostic Testing: An Updated Practice Parameter</description>
  </link>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 10, 2020</study_first_submitted>
  <study_first_submitted_qc>August 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 12, 2020</study_first_posted>
  <last_update_submitted>August 10, 2020</last_update_submitted>
  <last_update_submitted_qc>August 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>April 5, 2021</submitted>
    <returned>April 29, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

